The clinical-stage biotechnology company announced an 85% remission rate in evaluable frontline AML patients treated with mipletamig in combination with standard-of-care venetoclax and azacitidine.

AML patientsMipletamig combination enables rare pathway to transplant in a previously ineligible unfit patientNo dose-limiting toxicities observed among ...

AML patients Mipletamig combination enables rare pathway to transplant in a previously ineligible unfit patient No dose-limiting toxicities observed among evaluable patients; safety profile remains ...

Personalized drug treatments have outperformed chemotherapy for leukemia patients in a trial led by Leeds researchers. Newly ...

The VERONA trial evaluated the safety and efficacy of venetoclax with azacitidine in treatment-naïve adults with higher-risk MDS.

AbbVie's Phase 3 VERONA trial in HR-MDS showed no overall survival benefit for venetoclax-azacitidine; existing uses of ...

AbbVie (ABBV) announced the global Phase 3 Vevrona trial evaluating venetoclax in combination with azacitidine in the treatment of newly diagnosed higher-risk myelodysplastic syndrome did not meet the ...

AbbVie is deploying more capital into its pipeline, which features 50 programs in mid- and late-stage development and over ...

Genentech, a member of the Roche Group (RHHBY), and AbbVie announced that The Phase III VERONA study, which evaluated Venclexta or venetoclax in combination with azacitidine for patients with ...

The AbbVie-Roche cancer drug venetoclax failed to meet its primary endpoint in a phase 3 trial to treat newly diagnosed ...

SOUTH SAN FRANCISCO, Calif.-- (BUSINESS WIRE)--Jun 16, 2025-- ...

AbbVie (ABBV) stock in focus after a Phase 3 trial setback for leukemia therapy venetoclax marketed with Roche (RHHBY) in ...